Granules India shares gain after US unit gets EIR from USFDA
Granules India Limited's US subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received an Establishment Inspection Report (EIR) from the USFDA for its active pharmaceutical ingredient (API) manufacturing facility in Visakhapatnam, India. The inspection was classified as 'No Action Indicated' (NAI), signifying a positive regulatory outcome with no observations cited.
Jun 03 2026 12:44:54
Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India's US subsidiary, Granules Pharmaceuticals Inc., received an Establishment Inspection Report (EIR) from the US FDA for its Chantilly facility. The report has a Voluntary Action Indicated (VAI) classification following four Form 483 observations during the inspection.
Jun 03 2026 11:48:10
Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Granules management will meet with analysts and investors on June 03, 2026, in Hyderabad. The company confirmed that no unpublished price-sensitive information would be shared during these meetings.
May 28 2026 16:37:02
Granules India Ltd-$ - 532482 - Transcript Of The Earnings Conference Call For Q4 And Financial Year Ended On March 31, 2026.
Granules reported strong Q4 FY26 financial performance, with revenue up 23% YoY to Rs.14,706 million and PAT rising 33% to Rs.2,016 million. Full-year FY26 revenue grew 20% to Rs.53,656 million, demonstrating stabilization and strengthened fundamentals.
May 05 2026 15:25:51
Granules India Limited
Granules India conducted its Q4 FY26 earnings conference call, highlighting strong financial performance with 23% YoY revenue growth and improved gross margins. The company also discussed strategic progress in key segments like peptide CDMO and regulatory readiness.
May 05 2026 15:21:45
Read More